For Health Professionals

Emerging science supports the use of cannabis for medical purposes. We understand that the decision to prescribe medical cannabis as a therapeutic alternative may not be an easy one because of limited evidence available and/or misconceptions related to cannabis. This is why we have developed a number of quick guides to help you determine if medical cannabis is right for your patient, and which cannabinoid and dosage, will best meet the needs of each individual.

LiV products

Our products are designed keeping patient needs in mind. All products are “medical grade and full spectrum/whole plant”

LiV – cartridges

COMING

SOON

COMING

SOON

LiV – Critical Kush – Dried Flower

CRIT

ICAL

KUSH

R805.00 Incl. VAT

7g  ·  R115 / g

LiV – Slurricane – Dried Flower

SLU

RRI

CANE

R1,150.00 Incl. VAT

10g  ·  R115 / g

LiV – Strain Discovery pack

STRAIN

DIS

COV

ERY

PACK

R4,600.00 Incl. VAT

40g  ·  R115 / g

LiV – Blueberry – Dried Flower

BLUE

BERRY

R 1,150.00 Incl. VAT

10g  ·  R115 / g

LiV – Black Cherry Punch – Dried Flower

BLACK

CHERRY

PUNCH

R1,150.00 Incl. VAT

10g  ·  R115 / g

LiV – Black Cherry Punch – Pre-Milled – No Trim

BLACK

CHERRY

PUNCH

R650.00 Incl. VAT

5g  ·  R130 / g

LiV – Black Cherry Punch – Pre-Rolls

BLACK

CHERRY

PUNCH

R787.50 Incl. VAT

5, 25g  ·  R150 / g

LiV – Cape Cookies

CAPE

COOKIES

10g  ·  R115 / g

LiV – Triangle Kush Mints - Dried Flowers

TRIANGLE

KUSH

MINT

LiV – Banana Exodus - Pre-milled

EXODUS

BANANA

LiV – Banana Exodus - Pre-Rolls

EXODUS

BANANA

LiV – Coming soon

SOON

COMING

Important Safety Information & Indications

Warnings & Precautions

Medicinal cannabis can cause dose-related transaminase elevations. Concomitant use of valproate and elevated transaminase levels at baseline increase this risk. Transaminase and bilirubin levels should be obtained prior to starting treatment, at one, three, and six months after initiation of treatment, and periodically thereafter, or as clinically indicated. Resolution of transaminase elevations occurred with discontinuation of Medicinal cannabis, reduction of Medicinal cannabis and/or concomitant valproate, or without dose reduction. For patients with elevated transaminase levels, consider dose reduction or discontinuation of Medicinal cannabis or concomitant medications known to affect the liver (e.g., valproate or clobazam). Dose adjustment and slower dose titration is recommended in patients with moderate or severe hepatic impairment. Consider not initiating Medicinal cannabis in patients with evidence of significant liver injury.

Medicinal cannabis can cause somnolence and sedation that generally occurs early in treatment and may diminish over time; these effects occur more commonly in patients using clobazam and may be potentiated by other CNS depressants.

Antiepileptic drugs (AEDs), including Medicinal cannabis, increase the risk of suicidal thoughts or behavior. Inform patients, caregivers, and families of the risk and advise to monitor and report any signs of depression, suicidal thoughts or behavior, or unusual changes in mood or behavior. If these symptoms occur, consider if they are related to the AED or the underlying illness.

As with most AEDs, Medicinal cannabis should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus.

Pregnancy:

Medicinal cannabis should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Drug Interactions:

Strong inducers of CYP3A4 and CYP2C19 may affect medicinal cannabis exposure. Medicinal cannabis may affect exposure to CYP2C19 substrates (e.g., clobazam, diazepam, stiripentol), orally administered P-gp substrates, or other substrates (see full Prescribing Information). Consider dose reduction of orally administered everolimus, with appropriate therapeutic drug monitoring, when everolimus is combined with medicinal cannabis. A lower starting dose of everolimus is recommended when added to medicinal cannabis therapy. Concomitant use of medicinal cannabis and valproate increases the incidence of liver enzyme elevations. Pneumonia was observed more frequently with concomitant use of medicinal cannabis and clobazam. Dosage adjustment of medicinal cannabis or other concomitant medications may be necessary.

We believe in the natural potential of cannabis

Contact us

Hi, we’re LiV, a medicinal cannabis brand.

This section of the website is reserved for healthcare professionals as it contains information about prescription medicines.

Please confirm you are a healthcare professional to continue.

By clicking yes, you agree to the Privacy Policy and Terms & Conditions